Annexin Pharmaceuticals AB (publ) (ANNX.ST)
SEK 0.31
(0.32%)
SEK 0.31
(0.32%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -21.41 Million SEK | 31.17% |
| 2022 | -31.11 Million SEK | 37.12% |
| 2021 | -49.47 Million SEK | -172.88% |
| 2020 | -18.13 Million SEK | -349.26% |
| 2019 | -4.03 Million SEK | 86.43% |
| 2018 | -29.73 Million SEK | -111.91% |
| 2017 | -14.03 Million SEK | -4.17% |
| 2016 | -13.47 Million SEK | -6251.14% |
| 2015 | 219 Thousand SEK | 119.32% |
| 2014 | -1.13 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -7.87 Million SEK | 63.25% |
| 2024 Q2 | -37.35 Million SEK | -374.61% |
| 2024 Q3 | -25.64 Million SEK | 31.36% |
| 2023 Q2 | -17.28 Million SEK | 15.48% |
| 2023 Q1 | -20.44 Million SEK | 34.29% |
| 2023 FY | -21.41 Million SEK | 31.17% |
| 2023 Q4 | -21.41 Million SEK | -1541.0% |
| 2023 Q3 | -1.3 Million SEK | 92.45% |
| 2022 FY | -31.11 Million SEK | 37.12% |
| 2022 Q4 | -31.11 Million SEK | 15.32% |
| 2022 Q3 | -36.74 Million SEK | -6.7% |
| 2022 Q2 | -34.43 Million SEK | 11.86% |
| 2022 Q1 | -39.07 Million SEK | 21.03% |
| 2021 Q4 | -49.47 Million SEK | -596.01% |
| 2021 Q1 | -3.32 Million SEK | 81.67% |
| 2021 Q2 | -15.23 Million SEK | -358.45% |
| 2021 FY | -49.47 Million SEK | -172.88% |
| 2021 Q3 | -7.1 Million SEK | 53.35% |
| 2020 Q2 | -39.68 Million SEK | 24.86% |
| 2020 Q1 | -52.81 Million SEK | -1208.5% |
| 2020 Q3 | -30.76 Million SEK | 22.47% |
| 2020 Q4 | -18.13 Million SEK | 41.06% |
| 2020 FY | -18.13 Million SEK | -349.26% |
| 2019 Q3 | -11.13 Million SEK | 30.95% |
| 2019 Q1 | -22.35 Million SEK | 24.84% |
| 2019 FY | -4.03 Million SEK | 86.43% |
| 2019 Q4 | -4.03 Million SEK | 63.75% |
| 2019 Q2 | -16.12 Million SEK | 27.86% |
| 2018 Q1 | -5.24 Million SEK | 62.65% |
| 2018 FY | -29.73 Million SEK | -111.91% |
| 2018 Q4 | -29.73 Million SEK | 15.01% |
| 2018 Q3 | -34.98 Million SEK | 16.38% |
| 2018 Q2 | -41.84 Million SEK | -698.34% |
| 2017 Q3 | -24.03 Million SEK | 27.6% |
| 2017 Q4 | -14.03 Million SEK | 41.62% |
| 2017 FY | -14.03 Million SEK | -4.17% |
| 2017 Q1 | -4.53 Million SEK | 66.32% |
| 2017 Q2 | -33.2 Million SEK | -631.81% |
| 2016 Q1 | 781.35 Thousand SEK | 0.0% |
| 2016 Q4 | -13.47 Million SEK | 0.0% |
| 2016 FY | -13.47 Million SEK | -6251.14% |
| 2015 FY | 219 Thousand SEK | 119.32% |
| 2014 FY | -1.13 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alzinova AB (publ) | -21.22 Million SEK | -0.89% |
| Amniotics AB (publ) | -5.63 Million SEK | -280.238% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -890.976% |
| BioArctic AB (publ) | -606.58 Million SEK | 96.47% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 496.574% |
| Saniona AB (publ) | 40.44 Million SEK | 152.946% |
| Simris Alg AB (publ) | 85.07 Million SEK | 125.172% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 93.581% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -2220.152% |
| NextCell Pharma AB | -46.79 Million SEK | 54.232% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 27.118% |
| AcouSort AB (publ) | -23.98 Million SEK | 10.719% |
| Active Biotech AB (publ) | -33.2 Million SEK | 35.497% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 57.188% |
| Camurus AB (publ) | -1.16 Billion SEK | 98.162% |
| Cantargia AB (publ) | -139.74 Million SEK | 84.676% |
| Genovis AB (publ.) | -43.94 Million SEK | 51.264% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 74.427% |
| Mendus AB (publ) | -96.29 Million SEK | 77.761% |
| Kancera AB (publ) | -45.69 Million SEK | 53.132% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 73.948% |
| LIDDS AB (publ) | -13.51 Million SEK | -58.489% |
| Lipum AB (publ) | -8.46 Million SEK | -152.983% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 32.925% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 140.236% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -12.356% |
| OncoZenge AB (publ) | -12.62 Million SEK | -69.597% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 112.895% |
| Xintela AB (publ) | -7.8 Million SEK | -174.235% |
| Ziccum AB (publ) | -2.13 Million SEK | -902.106% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 84.499% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 83.463% |
| CombiGene AB (publ) | -101.44 Million SEK | 78.889% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 73.912% |
| Intervacc AB (publ) | -88.16 Million SEK | 75.709% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 57.113% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 204.412% |
| Corline Biomedical AB | -17.01 Million SEK | -25.882% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 74.428% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 45.622% |
| Aptahem AB (publ) | 2.9 Million SEK | 836.254% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 93.492% |
| Fluicell AB (publ) | -2.76 Million SEK | -675.063% |
| Biovica International AB (publ) | -58.73 Million SEK | 63.541% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 52.639% |
| Abliva AB (publ) | -57.24 Million SEK | 62.587% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 89.001% |
| 2cureX AB (publ) | -13.4 Million SEK | -59.778% |
| I-Tech AB | -83.26 Million SEK | 74.28% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 115.897% |
| Cyxone AB (publ) | -16.67 Million SEK | -28.464% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 61.681% |
| Biosergen AB | -1.88 Million SEK | -1037.281% |
| Nanologica AB (publ) | -9.38 Million SEK | -128.11% |
| SynAct Pharma AB | -61.75 Million SEK | 65.324% |
| BioInvent International AB (publ) | -236.3 Million SEK | 90.938% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -61.877% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 67.999% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -313.344% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -2.991% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -620.559% |